Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 7/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879793 | 0.86 | ENPP1 (0.52) | ENPP1HTTSMN1; SMN2GAA | |
| SCHEMBL4879548 | 0.86 | ENPP1 (0.52) | ENPP1HTTSMN1; SMN2CYP3A4GAA | |
| SCHEMBL2589386 | 0.74 | ENPP1 (0.53) | ENPP1HTTSMN1; SMN2CYP3A4GAA | |
| SCHEMBL7310843 | 0.73 | SLC33A1 (0.41) | — | |
| SCHEMBL5232567 | 0.72 | MAPT (0.44) | ENPP1HTTSMN1; SMN2GAAMEN1 | |
| SCHEMBL2582203 | 0.72 | ENPP1 (0.51) | ENPP1HTTSMN1; SMN2GAATSHR | |
| SCHEMBL14337399 | 0.72 | MBOAT4 (0.38) | MEN1KMT2ALMNAMAPK1ALDH1A1 | |
| SCHEMBL9770335 | 0.71 | HSD17B10 (0.56) | ENPP1HTTSMN1; SMN2CYP3A4MEN1 | |
| SCHEMBL3318957 | 0.69 | HTT (0.45) | ENPP1HTTSMN1; SMN2GAAMEN1 | |
| SCHEMBL10493808 | 0.69 | HSD17B10 (0.50) | ENPP1HTTSMN1; SMN2GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188494-A1 | Use Of 5-Alkyl-6-Phenylalkyl-7-Aminoazolopyrimidines, Novel Azolopyrimidines, Processes For Their Preparation And Compositions Comprising Them | BASF AKTIENGESELLSCHAFT (DE) | 2008-08-07 | — | — | US | disclosed |
| EP-1876899-A2 | USE OF 5-ALKYL-6-PHENYLALKYL-7-AMINO-AZOLOPYRIMIDINES, NOVEL AZOLOPYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, AND AGENTS CONTAINING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114405-A2 | USE OF 5-ALKYL-6-PHENYLALKYL-7-AMINO-AZOLOPYRIMIDINES, NOVEL AZOLOPYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, AND AGENTS CONTAINING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188494-A1 | Use Of 5-Alkyl-6-Phenylalkyl-7-Aminoazolopyrimidines, Novel Azolopyrimidines, Processes For Their Preparation And Compositions Comprising Them | RRM2, PNP, NT5C3B | ENPP1 818/4885HTT 2740/4885SMN1; SMN2 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.